Search research articles
Contact Us
Filters
Showing results (401-410 of 940) with videos related to
Page
of 94
Sort By:
Journal of Neuropathology and Experimental Neurology
|
October 8, 2014
How stemlike are sphere cultures from long-term cancer cell lines? Lessons from mouse glioma models
Mushfika Ahmad, Karl Frei, Edith Willscher, et al.
Cancers
|
July 2, 2021
Patients with Primary Central Nervous System Lymphoma Not Eligible for Clinical Trials: Prognostic Factors, Treatment and Outcome
Sabine Seidel, Michelle Margold, Thomas Kowalski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2021
Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071-22072 and CORE Trials
Julia Furtner, Michael Weller, Michael Weber, et al.
Journal of Neuro-Oncology
|
February 10, 2018
Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?
Caroline Happold, Thierry Gorlia, L Burt Nabors, et al.
Journal of Neurology
|
April 21, 2007
Treatment of active secondary progressive multiple sclerosis with treosulfan
Heinz Wiendl, Bernd C Kieseier, Robert Weissert, et al.
Brain : a Journal of Neurology
|
May 11, 2021
Survival of brain tumour patients with epilepsy
Maximilian Mastall, Fabian Wolpert, Dorothee Gramatzki, et al.
The European Journal of Neuroscience
|
December 6, 2003
Modulation of neuronal activity by the endogenous pentapeptide QYNAD
Sven G Meuth, Thomas Budde, Hüseyin Duyar, et al.
Neuro-Oncology
|
January 20, 2021
Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez
Patrick Y Wen, Michael Weller, Ennio Antonio Chiocca, et al.
Journal of the National Cancer Institute
|
April 5, 2017
Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363
Michael Weller, Patrick Roth, Felix Sahm, et al.
Clinical Neuropharmacology
|
February 10, 2012
Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort
Ulf Kallweit, Ilijas Jelcic, Nathalie Braun, et al.
Page
of 94
Search research articles
Search
Showing results (401-410 of 940) with videos related to
Sort By:
Page
of 94
Journal of Neuropathology and Experimental Neurology
|
October 8, 2014
How stemlike are sphere cultures from long-term cancer cell lines? Lessons from mouse glioma models
Mushfika Ahmad, Karl Frei, Edith Willscher, et al.
Cancers
|
July 2, 2021
Patients with Primary Central Nervous System Lymphoma Not Eligible for Clinical Trials: Prognostic Factors, Treatment and Outcome
Sabine Seidel, Michelle Margold, Thomas Kowalski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2021
Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071-22072 and CORE Trials
Julia Furtner, Michael Weller, Michael Weber, et al.
Journal of Neuro-Oncology
|
February 10, 2018
Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?
Caroline Happold, Thierry Gorlia, L Burt Nabors, et al.
Journal of Neurology
|
April 21, 2007
Treatment of active secondary progressive multiple sclerosis with treosulfan
Heinz Wiendl, Bernd C Kieseier, Robert Weissert, et al.
Brain : a Journal of Neurology
|
May 11, 2021
Survival of brain tumour patients with epilepsy
Maximilian Mastall, Fabian Wolpert, Dorothee Gramatzki, et al.
The European Journal of Neuroscience
|
December 6, 2003
Modulation of neuronal activity by the endogenous pentapeptide QYNAD
Sven G Meuth, Thomas Budde, Hüseyin Duyar, et al.
Neuro-Oncology
|
January 20, 2021
Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez
Patrick Y Wen, Michael Weller, Ennio Antonio Chiocca, et al.
Journal of the National Cancer Institute
|
April 5, 2017
Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363
Michael Weller, Patrick Roth, Felix Sahm, et al.
Clinical Neuropharmacology
|
February 10, 2012
Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort
Ulf Kallweit, Ilijas Jelcic, Nathalie Braun, et al.
Page
of 94